Authors


Dana Holger, PharmD, MPH, AAHIVP

Latest:

Tricky Infusion Issues and Potential Solutions: OPAT Edition

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.




Brandon Garcia, PharmD, PGY2

Latest:

New Recommendations for Antibiotic Prophylaxis Prior to Dental Procedures

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.


Elizabeth Hastie, MD

Latest:

Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges

Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.


Sarah Green, PharmD, BCPS, BCIDP, AAHIVP

Latest:

Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.


Bala Subramanian, PhD

Latest:

Bugworks' Antibiotic BWC0977 Targets Resistant Pathogens

Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.


Theodore S. Rader IV, MD, MS

Latest:

Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?

Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.


Christina Yen, MD; Ahmed Abdul Azim, MD; and Preeti Mehrotra, MD, MPH

Latest:

From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination Strategies

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.


Nina Cosdon

Latest:

Unveiling Gender Disparities in Lyme Disease: A Critical Analysis of Persistent Illness

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?


Kaitlyn Jarrell, PharmD, BCPS, AAHIVP

Latest:

PrEP State of the Union: Adherence, Access, Uptake Issues

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.


Alyssa Walker, PharmD, BCPS, BCIDP

Latest:

Antibiotic De-Escalation: Is This the Right Outcome Measure?

The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.


Steven P. LaRosa, MD

Latest:

Ceftriaxone as Definitive OPAT for MSSA Bloodstream Infections

A cautious approach for now is warranted as well as a need for a randomized clinical trial.


Geena Kludjian, PharmD, BCIDP

Latest:

Employee Health After the COVID-19 Pandemic: Stronger Than Yesterday

For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.


Olivia Mobarakai, DO

Latest:

Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream Infections

With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.


Victoria Grant, PharmD

Latest:

Strengths and Limitations of T2Candida Implementation From an Antimicrobial Stewardship Perspective

This novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.



Daniel Chastain, PharmD, BCIDP, AAHIVP

Latest:

Clinical Considerations in Conducting Antifungal Susceptibility Testing

Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.


Eunice Kim, PharmD

Latest:

What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.


Connor Iapoce

Latest:

Survey Highlights Critical Role of Pharmacists in HCV Management

Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.


Kate Broderick, PhD

Latest:

mRNA Capping: A Component That Protects the COVID-19 Vaccine and Lends to its Effectiveness

Kate Broderick, PhD, molecular geneticist, discusses the mRNA capping technology and how it helps create stability to mRNA molecules within vaccines and guides them to cells.


Malki De Silva, MPH

Latest:

Recent Research Indicates That We're Falling Short on HBV Elimination Targets

Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.


Buddy Creech, MD, MPH

Latest:

Safety and Immunogenicity Results For Mpox Vaccine MVA-BN in Adolescents Amid Rising Concerns

Buddy Creech, MD, MPH, assures that the interim findings of the study indicate adolescents produced a stronger immune response compared to adults, with minimal adverse effects.


Rick Starlin, MD

Latest:

The Variety of Variants in COVID-19

The evolution of the major variants, including the delta mutation.


Jacob Snowdin, DO

Latest:

CRAB-By No More?

Understanding the potential and limitations of new Acinetobacter baumannii active therapies.


Kevin Michael Reiter, MD, PA

Latest:

Practice Pearls for Treatment of Respiratory Infections

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.


Victoria Johnson

Latest:

HIV CRISPR Therapy Fast-Tracked by the FDA

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.


Lauren Massaro

Latest:

The US Will Transition to Trivalent Vaccines for Next Year's Influenza Season

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.


Tracy Zembles, PharmD

Latest:

Expanded Treatment Options for Multi-Drug Resistant Infections in Children

In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.


Alexandra Hanretty, PharmD,

Latest:

UTIs: Why Did You Have to Go and Make Things so Complicated?

Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.

© 2024 MJH Life Sciences

All rights reserved.